Trump's Obesity Drug Price Deal
Analysis based on 6 articles · First reported Nov 06, 2025 · Last updated Nov 07, 2025
The deal is expected to positively impact the pharmaceutical market by increasing access to GLP-1 obesity drugs, potentially boosting sales for Eli Lilly and Company and Novo Nordisk while also addressing public concerns about drug pricing. Expanded United States — Medicare and United States — Medicaid coverage could lead to broader adoption and revenue growth for these companies, though the price reductions might temper profit margins on individual prescriptions.
President Donald Trump announced a deal with drugmakers Eli Lilly and Company and Novo Nordisk to expand coverage and reduce prices for their popular obesity treatments, Zepbound and Wegovy. This initiative aims to make these GLP-1 receptor agonist drugs more accessible to millions of Americans, particularly United States — Medicare and United States — Medicaid patients, who have faced barriers due to high costs and limited insurance coverage. Under the agreement, United States — Medicare will begin covering obesity treatments next year, with qualifying patients paying $50 copays. Lower prices will also be phased in for uninsured individuals through the Trump administration's TrumpRx program, with average prices starting at $350 and dropping to $245 over two years. Eli Lilly and Company has committed to selling starter doses of Zepbound for $299 and additional doses for up to $449, representing $50 reductions. The deal also includes lower prices for state and federally funded United States — Medicaid programs and a $149 monthly cost for starting doses of new pill versions of the treatments, if approved. This move is part of the Trump administration's broader effort to rein in drug prices and address cost-of-living concerns among voters, following similar agreements with Pfizer and AstraZeneca.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard